Today’s C-suite executives in the life sciences must be experts in many disciplines. Pharm Exec examines the evolving role of the chief financial officer as not just a numbers and bottom-line risk manager but an integral contributor to overall corporate strategy and close partner to the CEO.
As market headwinds persist, our latest industry review of shareholder value reveals a sharp performance differential between companies that pursue a strategy of specialized therapeutic focus and those that continue to rely on line diversity, size and scale.
Pharm Exec convenes some of the industry’s top business development professionals and negotiators to talk about the current climate for biophamara dealmaking and the critical job of appraising new assets and their potential as market-worthy and transformative products for patients.
Do recent trends in the pharma and biotech M&A and equity markets signal a temporary lull - or a permanent drop? Peter Young reports.
After a sharp spike in revenues, this year’s audit finds our 25 companies doubling down to secure the operational efficiencies that promise to better align with an increasingly tightfisted payer community. Never before has market relevance been so firmly linked to customer reputation.
On June 30, the Centers for Medicare and Medicaid Services (CMS) released the first full year of data under The Affordable Care Act’s transparency program, also known as Open Payments or the "Sunshine Act." This included approximately 11.4 million records totaling about $6.5 billion in payments made to 607,000 physicians and 1,121 teaching hospitals by 1,444 reporting entities during 2014. Combined with CMS’s September 2014 release of 2013 data for the period Aug. 1, 2013 through Dec.
The American Medical Association invested heavily in DC influence in the first two quarters of 2015. PhRMA wasn't far behind. Casey McDonald reports.
Masters of the deal converge in New York to discuss the status of their trade and the forces propelling M&A, licensing, and partnerships in the life sciences for 2015.
The overall impression from the media is that the biotech industry is doing a great job inventing new drugs and treatments and that strong companies are getting the funding they need. But it's not that clear cut, writes Peter Young.
Fresh off Shire’s announcement to purchase NPS, CEO Dr. Flemming Ornskov sat down with PharmExec in San Francisco during the JP Morgan Healthcare Conference.
After a dip into negative territory in 2012, 2013 delivered a resurgence in sales revenues, but the turnaround only spotlights a larger trend: the growing divide between the big Pharmas and the more nimble players.
After fading to dreary summer stock for the past few years, dealmaking is today back to center stage, but with the major roles reversed- small biotech, yesterday’s understudy, now gets top billing, while big Pharma has to work harder for its close-up.
The pharma spin market is moving up a gear as companies see the imperative to tap into brand value. Allen Gove explains how understanding what the company is about is critical to bolstering the value of the product.
Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis, writes Pharm Exec Editor-in-Chief William Looney.
Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better, writes Peter Young.
Innovative pharmaceutical procurement has struggled to get the necessary mandate and attention from top management. But things may now be turning around, writes Philipp Polterauer.
Shareholder value now depends on finding pockets of "good" growth, in segments with fewer players, and where expenses can be tightly controlled.
Bill Trombetta surveys the landscape of pharma financials over the past year, and shows which companies rode the wave to the top of the industry in delivering value to shareholders.
Professor Bill Trombetta takes a snapshot of the "Glamour 24" companies shaping the pharma industry this year and beyond
Bill Trombetta expands his annual guide to stellar performance with the "Heavenly 27."
Pharmaceutical Executive
The latest dealmaking trends: Early-stage is back in favor. There's more money to be made in being acquired than in going public. And license deals are putting more on the back end.
Pharmaceutical Executive
Lovenox still needs a defense strategy to hold share, but it requires less investment as a specialty product. Instead, Lovenox should throw cash over to Acomplia, the putative future star of the Sanofi-Aventis portfolio.
